ClinicalTrials.Veeva

Menu

Sarcopenia and Related Factors in Coronavirus Disease 2019 (COVID-19) Following Intensive Care

K

Koç University

Status

Terminated

Conditions

Intensive Care Unit Acquired Weakness
Covid19
Sarcopenia

Treatments

Other: Standard care treatment for COVID-19 in Intensive Care Unit

Study type

Observational

Funder types

Other

Identifiers

NCT05474157
2020.221.IRB1.071

Details and patient eligibility

About

The primary aim of this study is to evaluate the patients who had pneumonia or severe acute respiratory distress syndrome (ARDS) due to COVID-19 in terms of sarcopenia and related factors following Intensive Care Unit (ICU).

The patients who had COVID-19 infection in the ICU and the patients who admitted to the 'Physical Medicine and Rehabilitation' clinic for other reasons during the pandemic period will be compared in terms of sarcopenia.

Full description

Patients with acute respiratory distress syndrome (ARDS) could develop muscle weakness associated with impairment of physical function defined as intensive care unit acquired weakness. Significant muscle loss occurs in the first week of the Intensive Care Unit (ICU) hospitalizations due to acute respiratory failure. Patients lose 18 percent of their body weight when discharged from the ICU. The presence of sepsis is known as the hypercatabolic process for the muscles. Hypophosphatemia and hypomagnesemia can cause respiratory muscle weakness. Fever and inflammation, use of muscle relaxant or sedatives may also cause muscle loss in intensive care during this period.

COVID-19 is an acute infection with a high risk of enormous cytokine storm exacerbating the clinical condition in acute respiratory distress syndrome and is thought to further increase the risk of muscle weakness.

The patients will be evaluated for hand grip strength, calf circumference measurement, 'Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls' (SARCF), SarQoL, timed up and go test, sit to stand test, and Short form-36.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients with ARDS or severe pneumonia due to COVID-19 hospitalized in intensive care unit
  • > 18 years old
  • Age and gender matched patients admitted to the 'Physical Medicine and Rehabilitation' clinic for control group

Exclusion criteria

  • Other diseases that may cause sarcopenia (cancer, non-respiratory organ failure and heart, liver or kidney failure)
  • Neurological diseases that may cause sarcopenia (stroke, spinal cord injury, muscle diseases)

Trial design

30 participants in 2 patient groups

Study group
Description:
15 patients Patients followed in the Intensive Care Unit due to COVID-19 infection
Treatment:
Other: Standard care treatment for COVID-19 in Intensive Care Unit
Control group
Description:
15 patients Patients who admitted to the 'Physical Medicine and Rehabilitation' clinic for other reasons during the pandemic period

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems